News >

Rova-T Underperforms in Phase II SCLC Trial

Jason Harris
Published: Thursday, Mar 22, 2018

Mike Severino, MD

Mike Severino, MD
Rovalpituzumab Tesirine (Rova-T) delivered disappointing preliminary results in the third-line setting for patients with relapsed/refractory small cell lung cancer (SCLC) with high DLL3 expression, according to findings from the single-arm, phase II TRINITY trial.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x